BioForce Nanosciences Holdings, Inc. BFNH
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.37% | -3.83% | -0.08% | 2.87% | 5.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.37% | -3.83% | -0.08% | 2.87% | 5.98% |
| Operating Income | -22.37% | 3.83% | 0.08% | -2.87% | -5.98% |
| Income Before Tax | 92.47% | 64.50% | -163.62% | -169.39% | -175.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.47% | 64.50% | -163.62% | -169.39% | -175.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.47% | 64.50% | -163.62% | -169.39% | -175.46% |
| EBIT | -22.37% | 3.83% | 0.08% | -2.87% | -5.98% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.70% | 66.59% | -136.31% | -144.85% | -153.70% |
| Normalized Basic EPS | -13.86% | 12.75% | 10.58% | 4.90% | -1.00% |
| EPS Diluted | 92.70% | 66.59% | -136.31% | -144.85% | -153.70% |
| Normalized Diluted EPS | -13.86% | 12.75% | 10.58% | 4.90% | -1.00% |
| Average Basic Shares Outstanding | 7.88% | 11.68% | 13.43% | 9.80% | 6.17% |
| Average Diluted Shares Outstanding | 7.88% | 11.68% | 13.43% | 9.80% | 6.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |